TCRX

TScan Therapeutics Inc

Add to Watchlist

Advanced Chart

1.800

-0.02(-1.099%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.8596

Open

1.840

VWAP

1.81

Vol

91.40K

Mkt Cap

102.15M

Low

1.790

Amount

165.76K

EV/EBITDA(TTM)

Total Shares

52.86M

-83.89M

EV/OCF(TTM)

P/S(TTM)

32.26

TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

1.73M

-20.54%

-0.290

+11.54%

1.68M

+152.63%

-0.325

+11.92%

1.98M

+88.75%

-0.327

+30.68%

Estimates Revision

The market is revising Upward the revenue expectations for TScan Therapeutics, Inc. (TCRX) for FY2025, with the revenue forecasts being adjusted by 55.34% over the past three months. During the same period, the stock price has changed by 23.29%.

Revenue Estimates for FY2025

Revise Upward

+55.34%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.2%

In Past 3 Month

Stock Price

Go Up

+23.29%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast TCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRX is 8.50 USD with a low forecast of 3.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.800

Low

3.00

Averages

8.50

High

12.00

Current: 1.800

Low

3.00

Averages

8.50

High

12.00

Needham

Gil Blum

Strong Buy

Reiterates

2025-04-08

Reason

Needham

Gil Blum

Price Target

2025-04-08

Reiterates

Strong Buy

Reason

Morgan Stanley

Maxwell Skor

Buy

Initiates

$10

2025-03-14

Reason

Morgan Stanley

Maxwell Skor

Price Target

$10

2025-03-14

Initiates

Buy

Reason

Morgan Stanley analyst Maxwell Skor assumed coverage of TScan Therapeutics with an Overweight rating and $10 price target. Recent Phase 1 ALLOHA data showed product candidates TSC-100 and TSC-101 outperformed the control arm with 8% of patients relapsing versus 33% in the control arm, notes the analyst, who is focused on additional data from the ALLOHA trial expected by year-end and safety/response data from the multiplex solid tumor program in the second half of 2025.

Barclays

Peter Lawson

Buy

Maintains

$14 → $3

2025-03-07

Reason

Barclays

Peter Lawson

Price Target

$14 → $3

2025-03-07

Maintains

Buy

Reason

Barclays lowered the firm's price target on TScan Therapeutics to $3 from $14 and keeps an Overweight rating on the shares post the Q4 report. The firm says that given the pullback in the stock, it "derisked the model" post the earnings print, focusing the model on transplant and head-neck with "conservative penetration." The analyst still sees upside in the shares.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$15

2025-03-06

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$15

2025-03-06

Reiterates

Strong Buy

Reason

Needham

Gil Blum

Strong Buy

Maintains

$11 → $9

2025-03-05

Reason

Needham

Gil Blum

Price Target

$11 → $9

2025-03-05

Maintains

Strong Buy

Reason

Needham

Gil Blum

Strong Buy

Reiterates

$11

2024-12-11

Reason

Needham

Gil Blum

Price Target

$11

2024-12-11

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for TScan Therapeutics Inc (TCRX.O) is -1.43, compared to its 5-year average forward P/E of -2.56. For a more detailed relative valuation and DCF analysis to assess TScan Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.56

Current PE

-1.43

Overvalued PE

-0.74

Undervalued PE

-4.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.53

Current EV/EBITDA

0.13

Overvalued EV/EBITDA

1.02

Undervalued EV/EBITDA

-2.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

19.42

Current PS

15.75

Overvalued PS

38.95

Undervalued PS

-0.11

Financials

Annual

Quarterly

FY2025Q2

YoY :

+473.88%

3.08M

Total Revenue

FY2025Q2

YoY :

+13.31%

-38.65M

Operating Profit

FY2025Q2

YoY :

+16.71%

-36.95M

Net Income after Tax

FY2025Q2

YoY :

-0.00%

-0.28

EPS - Diluted

FY2025Q2

YoY :

+27.54%

-34.55M

Free Cash Flow

FY2025Q2

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q2

YoY :

+207.96%

-1.89K

FCF Margin - %

FY2025Q2

YoY :

-79.66%

-1.20K

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 705.29% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

3.1M

USD

Months

6-9

0.0

USD

Months

0-12

389.9K

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 12447.81% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

4.3M

Volume

6-9

Months

503.2K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.9M

Volume

Months

6-9

15.5K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areBuying! The selling amount has increased 705.29% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

3.1M

USD

Months

6-9

0.0

USD

Months

0-12

389.9K

USD

Months

TCRX News & Events

Events Timeline

2025-08-12 (ET)

2025-08-12

07:04:38

TScan Therapeutics expects cash to fund operations into Q1 of 2027

2025-08-12

07:04:17

TScan Therapeutics reports Q2 EPS (28c), consensus (32c)

2025-05-06 (ET)

2025-05-06

07:04:45

TScan Therapeutics reports Q1 EPS (26c), consensus (28c)

News

1.0

05-28Newsfilter

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

9.0

05-23PRnewswire

New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

4.0

05-07Benzinga

HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $10

People Also Watch

SBFG

SB Financial Group Inc

Lument Finance Trust Inc

First Guaranty Bancshares Inc

Champions Oncology Inc

Core Molding Technologies Inc

FAQ

What is TScan Therapeutics Inc (TCRX) stock price today?

The current price of TCRX is 1.8 USD — it has decreased -1.1 % in the last trading day.

TCRX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

TCRX News & Events

Events Timeline

News

People Also Watch

FAQ

What is TScan Therapeutics Inc (TCRX) stock price today?

What is TScan Therapeutics Inc (TCRX)'s business?

What is the price predicton of TCRX Stock?

What is TScan Therapeutics Inc (TCRX)'s revenue for the last quarter?

What is TScan Therapeutics Inc (TCRX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for TScan Therapeutics Inc (TCRX)'s fundamentals?

How many employees does TScan Therapeutics Inc (TCRX). have?

What is TScan Therapeutics Inc (TCRX) market cap?